IWC
MTNB icon

Integrated Wealth Concepts’s Matinas BioPharma MTNB Stock Holding History

Integrated Wealth Concepts’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-502
Closed -$20K – 1042
2022
Q1 		$20K Hold
502
– – ﹤0.01% 932
2021
Q4 		$25K Sell
502
-12
-2% -$641 ﹤0.01% 978
2021
Q3 		$33K Sell
514
-700
-58% -$30.2K ﹤0.01% 933
2021
Q2 		$47K Buy
1,214
+990
+442% +$42.6K ﹤0.01% 795
2021
Q1 		$12K Buy
+224
New +$15K ﹤0.01% 732

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Integrated Wealth Concepts's MTNB Position: Q2 2022 in Review

Integrated Wealth Concepts sold out of Matinas BioPharma (MTNB) in Q2 2022, closing a stake of 502 shares — an estimated $20K sold.

Integrated Wealth Concepts first reported a position in MTNB in Q1 2021 and held it in 5 quarters. The position peaked at $47K in Q2 2021. 50 funds tracked by Wall St. Rank hold MTNB as of Q2 2022.

  • Integrated Wealth Concepts reported no remaining Matinas BioPharma position as of Q2 2022 after selling out during the quarter.
  • Integrated Wealth Concepts sold 502 Matinas BioPharma shares in Q2 2022, an estimated $20K.
  • Integrated Wealth Concepts first reported a position in Matinas BioPharma in Q1 2021 and held it in 5 quarters.
  • Integrated Wealth Concepts's Matinas BioPharma position peaked at $47K in Q2 2021.
  • 50 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2022.

Based on Integrated Wealth Concepts's 13F filing for Q2 2022, filed 8 Aug 2022.